WO2004041281A1 - Traitement du trouble hyperkinetique avec du donepezil - Google Patents

Traitement du trouble hyperkinetique avec du donepezil Download PDF

Info

Publication number
WO2004041281A1
WO2004041281A1 PCT/US2003/034815 US0334815W WO2004041281A1 WO 2004041281 A1 WO2004041281 A1 WO 2004041281A1 US 0334815 W US0334815 W US 0334815W WO 2004041281 A1 WO2004041281 A1 WO 2004041281A1
Authority
WO
WIPO (PCT)
Prior art keywords
donepezil
dystonia
treatment
ofthe
tremor
Prior art date
Application number
PCT/US2003/034815
Other languages
English (en)
Inventor
Kathryn Chung
Steven Johnson
Original Assignee
Oregon Health And Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health And Science University filed Critical Oregon Health And Science University
Priority to AU2003287433A priority Critical patent/AU2003287433A1/en
Publication of WO2004041281A1 publication Critical patent/WO2004041281A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the present invention concerns methods and pharmaceutical compositions for the treatment of hyperkinetic movement disorders including chorea and dystonic tremor.
  • Movement disorders can be classified into two basic categories: those characterized by disordered or excessive movement (referred to as “hyperkinesia” or “dyskinesia”), and those that are characterized by slowness, or a lack of movement (referred to as “hypokinesia,” “bradykinesia,” or “akinesia”).
  • An example of a “hyperkinetic” movement disorder is a tremor or a tic while Parkinson's disease can be classified as “hypokinetic,” because it is often characterized by slow, deliberate movements, or even freezing in place.
  • Neurologic movement disorders include ataxia, corticobasal degeneration, dyskinesias
  • dystonia generally, segmental, focal
  • dystonia including blepharospasm, spasmodic torticollis (cervical dystonia), writer's cramp (limb dystonia), laryngeal dystonia (spasmodic dysphonia), and oromandibular dystonia, essential tremor, hereditary spastic paraplegia, Huntington' s Disease, multiple system atrophy (Shy Drager Syndrome), myoclonus, Parkinson's Disease, progressive supranuclear palsy, restless legs syndrome, Rett Syndrome, spasticity due to stroke, cerebral palsy, multiple sclerosis, spinal cord or brain injury, Sydenham's Chorea, tardive dyskinesia/dystonia, tics, Tourette's Syndrome, and Wilson's Disease.
  • the present invention provides, by one of its aspects, a pharmaceutical composition for the amelioration of hyperkinetic movement disorders, comprising as an active ingredient, a pharmaceutically effective amount of a cholinesterase inhibitor, such as donepezil.
  • a cholinesterase inhibitor such as donepezil.
  • the present invention provides, by another of its aspects, use of donepezil for the preparation of a pharmaceutical composition for the amelioration of hyperkinetic movement disorders.
  • the pharmaceutical composition comprises about 1 mg to about 50 mg of donepezil.
  • the pharmaceutical composition comprises about 2 mg to about 25 mg of donepezil.
  • the invention further provides a method for ameliorating hyperkinetic movement disorder, comprising administering to a subject in need of such treatment a therapeutically effective amount of donepezil.
  • the method comprises administering about 1 mg to about 50 mg of donepezil to the subject per day.
  • the method comprises administering about 2 mg to about 25 mg of donepezil to the subject per day.
  • the dosage ofthe active ingredient should be tested empirically for each specific indication, and depends on various factors, such as the patient's weight, the length of time of administration ofthe donepezil, age, etc. Generally speaking, the dosage should be of about 1 to about 50 mg per day, preferably of about 2 to about 25 mg per day, most preferably of about 2.5 to about 10 mg per day.
  • the pharmaceutical composition ofthe invention may comprise donepezil and a pharmaceutically acceptable carrier.
  • the invention relates in one aspect to treatment of dystonia, which is a neurologic movement disorder characterized by sustained muscle contractions, usually producing twisting and repetitive movements or abnormal postures or positions. Almost all dystonic movements share a directional quality that is typically sustained, sometimes for an instant, as well as a consistency and predictability. Dystonia movements are directional, forcing the involved body part or region into an abnormal position, which is consistently present.
  • Dystonia can be classified by age at which symptoms appear. Symptoms may become apparent during childhood, adolescence, or adulthood. It can also classified by the area or areas ofthe body that are affected. Sustained muscle contractions and abnormal movement patterns may be limited to one area ofthe body; involve two or more areas ofthe body that are next to each other, as in segmental dystonia; or two or more areas ofthe body that are not next to each other (non segmental or multi focal); or be generalized in nature, including leg involvement and other areas ofthe body. Dystonia can also be classified by cause. It may occur as a primary condition (idiopathic dystonia) that is familial or occurs in the absence of a family history.
  • Dystonia may be associated with certain nondegenerative, neurochemical disorders (known as “dystonia plus syndromes") that are characterized by neurologic features, such as parkinsonism or myoclonus. Dystonia is also a primary feature of certain, usually hereditary, neurodegenerative disorders (so called “heredodegenerative dystonias").
  • Dystonia can be accompanied by dystonic . tremor.
  • Botulinum toxin is a biological therapeutic agent that can be effective in treating dystonia.
  • Botulinum toxin is a toxic protein produced by the bacterium Clostridium botulinum.
  • BTX can cause botulism, a severe form of food poisoning that is contracted through the ingestion of contaminated food products.
  • acetylcholine a neurotransmitter responsible for activation of muscle contraction.
  • BTX decreases inappropriate or excessive muscle contractions, allowing the affected area (e.g., arm, neck, leg, eyelid, etc.) to assume a more normal position or posture.
  • Benzodiazepines are a class of drugs that interfere with chemical activities in the nervous system and brain, serving to reduce communication between nerve cells. Such medications may relax muscles and ease symptoms associated with dystonia. Benzodiazepines are oral medications that may be used to treat focal, segmental, and generalized dystonias. Diazepam (Valium®) and clonazepam (Klonopin®) are two types of benzodiazepines most commonly used to treat dystonia. The major side effect of these drugs is drowsiness, which may be controlled by lowering the dose. At relatively high doses, side effects may include depression, personality changes, or, in severe cases, psychosis.
  • Baclofen (Lioresal®) is used to treat individuals with spasticity, but it has also been administered to some patients with dystonia. Baclofen' s primary site of action is the spinal cord where it reduces the release of neurotransmitters that stimulate muscle activity (GAB A agonist stimulating GABAB autoreceptor). Baclofen has been used to treat both primary and secondary dystonias, and may be administered orally or through a surgically implanted pump that delivers the drug directly to the spinal cord (intrathecal baclofen).
  • Anticholinergic drugs block the action ofthe neurotransmitter acetylcholine, thereby deactivating muscle contractions. These drugs are administered orally and used to treat focal, segmental, and generalized dystonias. Trihexyphenidyl (Artane®) and diphenhydramine
  • Bodryl® are the most common anticholinergic agents used to treat dystonia. This form of therapy may be more beneficial in children, as they may be able to tolerate higher doses of trihexphenidyl than adults. Greater therapeutic benefits may also occur in patients who initiate drug therapy early during the course of their disease. Side effects may be severe, particularly at higher doses, and may include confusion, drowsiness, hallucinations, forgetfulness, personality changes, dry mouth, blurred vision, and urinary retention.
  • Dopamine blocking or dopamine depleting agents may be used to treat some patients with dystonia.
  • the possible positive effect of these agents is a paradox since dopamine blockers may also cause dystonia. Nonetheless, these agents have been shown to be effective in some patients.
  • tetrabenazine is the most widely used dopamine blocking agent.
  • tetrabenazme may be combined with lithium, which may help to lessen side effects such as slowed movements and depression.
  • Other dopamine blockers are not as commonly used, since they may be more likely to evoke tardive dystonia.
  • the neuroleptic drugs clozapine and olanzapine may be useful for the treatment of dystonia and may be less likely to cause tardive dystonia.
  • the acetylcholesterase inhibitor donepezil HCl also known as Aricept®, has been used to treat patients with Alzheimer's Disease.
  • donepezil has not been shown to be effective in other conditions such as progressive supranuclear palsy (Litvan, I. et al, Neurology 57:467-473, 2001), or Parkinson's Disease with dementia, according to a report by Aarsland, D. et al. as reported at www.wemove.org in 2001.
  • Donepezil is also known chemically as ( ⁇ )-2,3- dihydro-5,6-dimethoxy-2-[[l-(phenylmethyl)-4-piperidinyl]methyl]-lH-inden-l-one hydrochlori.de, and also as E2020.
  • hyperkinetic movement disorders refers to conditions such as tremor, chorea, tics, dyskinesia, and dystonia, including dystonic tremor.
  • hyperkinetic movement disorders can be classified generally into several categories, including tics, tremors, dyskinesia, and chorea.
  • Tremors can be classified as essential and dystonic, with essential being the more common ofthe two.
  • Dyskinesias can be idiopathic and tardive.
  • amelioration refers to a decrease in the abnormal involuntary movements characterizing hyperkinetic movement disorders, as can be determined for example, by using the Abnormal Involuntary Movement Scale (ALMS).
  • ALMS Abnormal Involuntary Movement Scale
  • the term "effective amount” refers to an amount that brings about a reduction in the ALMS.
  • Essential tremor is a common, slowly and variably progressive neurologic movement disorder characterized by involuntary, rhythmic, "back and forth” movements (i.e., tremor) of a body part or parts.
  • tremor is primarily a "postural” or “kinetic” tremor or may be a combination of both types: i.e., tremor occurs while voluntarily maintaining a fixed position against gravity (postural tremor) and/or when conducting self directed, targeted actions (kinetic intention tremor).
  • postural tremor postural tremor
  • kinetic intention tremor a combination of both types: i.e., tremor occurs while voluntarily maintaining a fixed position against gravity (postural tremor) and/or when conducting self directed, targeted actions.
  • both hands are affected, although the condition may sometimes initially be noted in the dominant hand. ET also frequently affects the head, with tremor occurring in a horizontal pattern in most patients and the remainder affected by vertical tremors.
  • Huntington' s disease is a hereditary, progressive, neurodegenerative disorder primarily characterized by the development of emotional, behavioral, and psychiatric abnormalities; gradual deterioration of thought processing and acquired intellectual abilities (dementia); and movement abnormalities, including involuntary, rapid, irregular jerky movements (chorea) ofthe face, arms, legs, or trunk.
  • HD may be inherited as an autosomal dominant trait or, less commonly, appear to occur randomly for unknown reasons (sporadically).
  • the disorder results from abnormally long sequences or "repeats" of certain coded instructions (i.e., unstable expanded CAG repeats) within a gene (located on chromosome pl6.3).
  • Progressive nervous system dysfunction associated with HD results from loss of neurons in certain areas ofthe brain, including the basal ganglia and cerebral cortex.
  • Parkinson's disease is a slowly progressive degenerative disorder ofthe central nervous system characterized by slowness or lack of movement (bradykinesia), rigidity, postural instability, and tremor primarily while at rest. Additional characteristics include a shuffling, unbalanced manner of walking; forward bending or flexion ofthe trunk; a fixed or "mask like" facial expression; weakness ofthe voice; abnormally small, cramped handwriting
  • micrographia depression; or other symptoms and findings. Such abnormalities may result from progressive loss of nerve cells within a certain region ofthe substantia nigra ofthe brain and the associated depletion ofthe neurotransmitter dopamine.
  • Tardive dyskinesia is a movement disorder that may result from extended therapy with certain antipsychotic medications such as haloperidol.
  • the condition is characterized by involuntary, rhythmic movements ofthe face, jaw, mouth, and tongue, such as lip pursing, chewing movements, or protrusion ofthe tongue. Facial movements are sometimes accompanied by involuntary, jerky or writhing motions (choreoathetoid movements) ofthe trunk, arms, and legs. In some patients, symptoms discontinue months or years after withdrawal of antipsychotic therapy. However, in others, the condition may not be reversible.
  • Tardive dystonia is a form of dyskinesia characterized by chronic dystonia due to administration of medications that block dopamine D2 receptors (dopamine receptor antagonists), such as certain antipsychotic agents.
  • dopamine D2 receptors dopamine receptor antagonists
  • Dopamine receptors are molecules on the surfaces of receiving nerve cells that are sensitive to stimulation by dopamine, a neurotransmitter that controls movement and balance.
  • Dystonia is a neurologic movement disorder characterized by sustained muscle contractions that often result in repetitive twisting motions or unusual postures or positions.
  • Tardive dystonia is the most common form of secondary dystonia, specifically, dystonia that results from certain environmental factors or "insults" that affect the brain. In adults, tardive dystonia often initially affects facial or neck muscles. Dystonia may remain limited to such regions or extend to affect adjacent muscles ofthe trunk and arms. Children are more likely to be affected by generalized dystonia that involves muscles ofthe trunk and legs.
  • Tics are defined as involuntary, compulsive, stereotypic muscle movements or vocalizations that abruptly interrupt normal motor activities. These repetitive, purposeless motions (motor tics) or utterances (vocal tics) may be simple or complex in nature; may be temporarily suppressed; and are often preceded by a "foreboding" sensation or urge that is temporarily relieved following their execution. Simple tics include abrupt, isolated movements, such as repeated facial twitching, blinking, or shoulder shrugging, and simple sounds, including grunting, throat clearing, or sighing.
  • Complex tics may involve more sustained, complex movements, such as deep knee bending or leg kicking, or complex vocalizations, including repeating another person's words or phrases (echolalia) or, rarely, explosive cursing (coprolalia).
  • Tourette syndrome is defined as the presence of multiple motor and vocal tics for at least one year, changes in the nature ofthe tics (e.g., complexity, severity, anatomical location) during the course ofthe disorder, and symptom onset before age 21.
  • the centrally active cholesterase inhibitor donepezil was used to treat a variety of patients with hyperkinetic movement disorders.
  • the diagnoses included idiopathic chorea, idiopathic generalized dystonia, essential tremor, dystonic tremor, and oromandibular dyskinesia. Results from patients showing improvement are shown in Table 1. Response was judged by clinical exam and history. Table 1 The results indicate that raising brain acetylcholine may ameliorate a variety of hyperkinetic movement disorders. The most impressive result has been achieved in patients with tremor and concomitant dystonia, where markedly positive results were consistently found. While donepezil has a plasma half life of 70 hours, some patients have required dosing usually twice a day to control symptoms. These open label results suggest that acetylcholinesterase inhibitors are useful for treating hyperkinetic movement disorders, particularly chorea and dystonia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques permettant de traiter le trouble hyperkinétique, y compris les tremblements dystoniques.
PCT/US2003/034815 2002-11-01 2003-10-31 Traitement du trouble hyperkinetique avec du donepezil WO2004041281A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287433A AU2003287433A1 (en) 2002-11-01 2003-10-31 Treatment of hyperkinetic movement disorder with donepezil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42293002P 2002-11-01 2002-11-01
US60/422,930 2002-11-01

Publications (1)

Publication Number Publication Date
WO2004041281A1 true WO2004041281A1 (fr) 2004-05-21

Family

ID=32312571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034815 WO2004041281A1 (fr) 2002-11-01 2003-10-31 Traitement du trouble hyperkinetique avec du donepezil

Country Status (3)

Country Link
US (1) US20040142970A1 (fr)
AU (1) AU2003287433A1 (fr)
WO (1) WO2004041281A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311272E (pt) * 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
MX339805B (es) 2010-04-22 2016-06-10 Intra-Cellular Therapies Inc Compuestos organicos.
MX2014012374A (es) * 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
EP2968320B1 (fr) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Composés organiques
KR102495941B1 (ko) 2013-12-03 2023-02-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
RU2016143091A (ru) 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2015154025A1 (fr) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Composés organiques
AU2017211791B2 (en) 2016-01-26 2022-01-06 Intra-Cellular Therapies, Inc. Organic compounds
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018175969A1 (fr) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
JP7223742B2 (ja) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019023063A1 (fr) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Composés organiques
EP3843738A4 (fr) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Nouvelles méthodes
EP3843739A4 (fr) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Nouvelles méthodes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0698390A1 (fr) * 1994-07-12 1996-02-28 Mitsubishi Chemical Corporation Utilisation de bifémélange pour la fabrication d'un médicament pour le traitement de l'hyperkinésie
US5633238A (en) * 1991-05-14 1997-05-27 Snorrason; Ernir Method for the treatment of schizophrenia
WO1997046527A1 (fr) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes de chlorhydrate de donepezil, et leur procede de production
US6034117A (en) * 1995-12-19 2000-03-07 A & Science Invest Ab Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method
EP1020469A2 (fr) * 1993-10-15 2000-07-19 Synaptech, Inc. Dérivés de la galanthamine, un procédé pour les préparer et leur utilisation comme medicaments
WO2001066114A1 (fr) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Nouvelles methodes reposant sur l'utilisation d'inhibiteurs de cholinesterase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633238A (en) * 1991-05-14 1997-05-27 Snorrason; Ernir Method for the treatment of schizophrenia
EP1020469A2 (fr) * 1993-10-15 2000-07-19 Synaptech, Inc. Dérivés de la galanthamine, un procédé pour les préparer et leur utilisation comme medicaments
EP0698390A1 (fr) * 1994-07-12 1996-02-28 Mitsubishi Chemical Corporation Utilisation de bifémélange pour la fabrication d'un médicament pour le traitement de l'hyperkinésie
US6034117A (en) * 1995-12-19 2000-03-07 A & Science Invest Ab Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method
WO1997046527A1 (fr) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes de chlorhydrate de donepezil, et leur procede de production
WO2001066114A1 (fr) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Nouvelles methodes reposant sur l'utilisation d'inhibiteurs de cholinesterase
US20020035128A1 (en) * 2000-03-03 2002-03-21 Raymond Pratt Methods for treating parkinson's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAROFF, S.N. ET AL.: "Treatment of tardive dyskinesia with donepezil", J CLIN PSYCHIATRY, vol. 62, no. 2, February 2001 (2001-02-01), pages 128 - 129, XP009028219 *
CAROFF, S.N. ET AL.: "Treatment of tardive dyskinesia with donepezil: a pilot study", J CLIN PSYCHIATRY, vol. 62, no. 10, October 2001 (2001-10-01), pages 772 - 775, XP009028230 *
HARDAN, A.Y. AND HANDEN, B.L.: "A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder", JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, vol. 12, no. 3, 2002, pages 237 - 241, XP009028232 *
MENDEZ M F ET AL: "USE OF DONEPEZIL FOR VASCULAR DEMENTIA: PRELIMINARY CLINICAL EXPERIENCE", JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCE, AMERICAN PSYCHIATRIC PRESS, WASHINGTON, DC, US, vol. 11, no. 2, 21 March 1999 (1999-03-21), pages 268 - 270, XP009008157, ISSN: 0895-0172 *
WILENS, T.E. ET AL.: "Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series", JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, vol. 10, no. 3, - 2000, pages 217 - 222, XP009028220 *

Also Published As

Publication number Publication date
US20040142970A1 (en) 2004-07-22
AU2003287433A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
US20040142970A1 (en) Treatment of hyperkinetic movement disorder with donepezil
KR101760139B1 (ko) 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
AU2001242568B2 (en) Treatment of movement disorders
Rychlicki et al. Vagus nerve stimulation: clinical experience in drug-resistant pediatric epileptic patients
EP1113797B1 (fr) Utilisation de la duloxetine pour le traitement de fibromyalgie
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
AU2001242568A1 (en) Treatment of movement disorders
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
US11135211B2 (en) Pimavanserin for treating impulse control disorder
EP2995305B1 (fr) Utilisation de bloqueurs des canaux potassiques pour traiter une paralysie motrice cérébrale
JP2011037877A (ja) ジスキネジーの治療
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
EP1154795B1 (fr) Dispositif permettant de traiter et de diagnostiquer le syndrome des impatiences des membres inferieurs
WO2019067413A1 (fr) Utilisation d'une formulation de fenfluramine pour réduire le nombre et les fréquences de crises convulsives dans des populations de patients
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
JPH09501664A (ja) 神経変性疾病におけるフルピルチンの一次及び二次神経保護作用
JP2023524039A (ja) Ｔ型カルシウムチャネルモジュレーターを使用する方法
EP0304294A2 (fr) Taliscanine et autres aristolactames pour le traitement des maladies neurologiques, maladie de Parkinson, maladie d'Alzheimer et de l'impuissance
JP5175015B2 (ja) ジスキネジーの治療
Bötzel et al. Strategies for treatment of gait and posture associated deficits in movement disorders: the impact of deep brain stimulation
JP2003523385A (ja) 神経変性疾患の治療法
CN111712239A (zh) 治疗不宁腿综合征的治疗剂
PL231163B1 (pl) Kombinacja i kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu bólowi z powodu umiarkowanych do ciężkich neuralgii o różnorodnym umiejscowieniu
CN108025003A (zh) 前额叶皮质处理病症，步态和肢体障碍治疗
WO2021210684A1 (fr) Agent thérapeutique contre l'hyperkinésie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP